The recently released Veeva Pulse Field Trend’s Report revealed clear findings that the utilization of field-medical liaisons pre-launch significantly impacts clinical practices’ adoption of a treatment by a 1.5- fold increase in the first 6-months post-launch compared to products not being supported with MSLs. Translating science into a commercially agreeable language early on is, without a doubt, critical.
In the final episode of the ParexelBiotech podcast series, “De-Risking Drug Development,” host Paul Bridges welcomes TMAC CEO David Hahn and an expert panel as they focus on post-launch market development and how to expand the use and value of your product over time.
Outsourcing can provide greater budget flexibility and control by allowing organizations to pay for the services and business functions they need, when they need them.
Outsourcing can provide greater budget flexibility and control by allowing organizations to pay for the services and business functions they need, when they need them.
